• Zeng-Mian Wang, Ze-Yu Wang, Chun-Jie Wei, and Yao-Jia Jiang.
• Third Ward of Neurology Department, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
• Medicine (Baltimore). 2020 Jun 19; 99 (25): e20702.

BackgroundThis protocol aims to assess the efficacy and safety of Botulinum Toxin Type A (BTTA) for the treatment of neuropathic pain (NPP) in patients with spinal cord injury (SCI).MethodsWe will retrieve databases in Cochrane Library, EMBASE, MEDLINE, Excerpta Medica Database, PsychINFO, the Allied and Complementary Medicine Database, and Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from the beginning to the March 1, 2020. We will consider any potential studies on assessing the efficacy and safety of BTTA for the treatment of NPP in patients with SCI without limitations of language and publication status. Cochrane risk of bias will be used to assess the risk of bias for all included trials. RevMan 5.3 software will be utilized to synthesize the extracted data and to analyze those data.ResultsThis study will appraise the efficacy and safety based on the current evidence of BTTA for the treatment of NPP in patients with SCI.ConclusionThis study will exert high quality clinical trials for exploring the efficacy and safety of BTTA in treating NPP in patients with SCI.Prospero Registration NumberPROSPERO CRD42020170474.

21 keywords...

hide…